Войти в систему Зарегистрироваться бесплатно

Inhibrx EV/Sales

Что обозначает EV/Sales в Inhibrx?

EV/Sales Inhibrx, Inc. является 707.77

Какое определение для EV/Sales?



Enterprise value to sales ratio compares a company’s total value to its sales.

ttm (trailing twelve months)

Enterprise value/sales is a valuation ratio that compares the company's enterprise value to its annual sales. It indicates the company's capacity to generate free cash flow. In general, the lower the ratio, the cheaper the company is.

EV/Sales is most often calculated as cash and cash equivalents subtracted from the sum of market capitalization and debt and divided by annual sales. Many analysts consider EV/sales to be a more accurate metric than Price/Sales as it considers both debt and equity holders in its calculation. One of the limitations of the calculation is that sales do not take into account a company's taxes or expenses.

EV/Sales компаний в Health Care сектор на NASDAQ по сравнению с Inhibrx

Что делает Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Компании с ev/sales похож на Inhibrx